



BAY 43-9006 - Novel RAF Kinase And VEGFR Inhibitor: Clinical Development Portfolio

BAY 43-9006	IND				
	Preclinical	Preparation	Phase I/II	Phase II	Phase III
Single Agent					
▪ Kidney					
▪ Liver					
▪ Multiple tumor types					
Chemotherapy Combinations					
▪ Melanoma: Carboplatin/Paclitaxel					
▪ Other (9)					



BAY 43-9006 - Encouraging Results at EORTC-NCI-AACR on September 29 in Geneva

- ▶ Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC) ¹⁾
- ▶ Preliminary assessment of BAY 43-9006 in advanced sarcoma patients using the randomized discontinuation study ²⁾
- ▶ A phase I study of BAY 43-9006, a novel RAF kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors ³⁾

1) G.K. Abou-Alfa¹, S. Ricci², D. Amadori³, A. Santoro⁴, A. Figer⁵, J. De Greve⁶, J. Douillard⁷, M. Moscovici⁸, B. Schwartz⁹, L.B. Saltz¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Ospedale S. Chiara, Pisa, Italy; ³Ospedale 'Morgagni Pierantoni', Forlì, Italy;
⁴Istituto Clinico Humanitas, Rozzano (MI), Italy; ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; ⁶AZ-VUB, Brussels, Belgium; ⁷Centre René Gauducheau, Nantes, France; ⁸Pharma Clinical Ltd, Nes-Zyona, Israel; ⁹Bayer Pharmaceuticals Corporation, West Haven, CT, USA
 2) J. Judson¹, S. Pacey¹, P. O'Dwyer¹, H. Xiong¹, A. Patnaik¹, T. Eisen¹, R. J. Lee², B. Schwartz², M. J. Ratain³
¹The Royal Marsden Hospital, London, UK; ²Bayer Pharmaceuticals Corporation, West Haven, CT, USA; ³University of Chicago Pritzker School of Medicine, Chicago, IL, USA
 3) A. Awada¹, A. Hendlisz¹, T. Gil¹, B. Schwartz², S. Bartholomeus¹, I. Delabaye¹, D. de Valeriola¹, E. Brendel³, C.G. Haase³, T. Delaunoy¹, M. Piccart¹; ¹Jules Bordet Institute, Brussels, Belgium; ²Bayer Pharmaceuticals Corporation, New Haven, CT, USA; ³Bayer HealthCare AG, Wuppertal, Germany

